Parallax Volatility Advisers’s Revance Therapeutics, Inc. RVNC Stock Holding History

Parallax Volatility Advisers’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,000	Closed	-$87.9K	–	2468
2023 Q4	$87.9K	Hold	10,000	–	–	﹤0.01%	1882
2023 Q3	$115K	Hold	10,000	–	–	﹤0.01%	1902
2023 Q2	$253K	Sell	10,000 -7,400	-43%	-$231K	﹤0.01%	1830
2023 Q1	$560K	Buy	+17,400	New	+$542K	﹤0.01%	1701
2022 Q4	–	Sell	-59,700	Closed	-$1.61M	–	3351
2022 Q3	$1.61M	Buy	59,700 +32,100	+116%	+$651K	﹤0.01%	1528
2022 Q2	$381K	Buy	+27,600	New	+$425K	﹤0.01%	2016
2019 Q1	–	Sell	-18,000	Closed	-$362K	–	4261
2018 Q4	$362K	Hold	18,000	–	–	﹤0.01%	1597
2018 Q3	$447K	Hold	18,000	–	–	﹤0.01%	1466
2018 Q2	$494K	Buy	+18,000	New	+$541K	﹤0.01%	1276

Other funds holding RVNC

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parallax Volatility Advisers's RVNC Position: Q3 2023 in Review

Parallax Volatility Advisers sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2023, closing a stake of 10,085 shares — an estimated $194K sold.

Parallax Volatility Advisers first reported a position in RVNC in Q4 2017 and held it in 4 quarters. The position peaked at $1.24M in Q4 2017. 186 funds tracked by Wall St. Rank hold RVNC as of Q3 2023.

Parallax Volatility Advisers reported no remaining Revance Therapeutics, Inc. position as of Q3 2023 after selling out during the quarter.
Parallax Volatility Advisers sold 10,085 Revance Therapeutics, Inc. shares in Q3 2023, an estimated $194K.
Parallax Volatility Advisers first reported a position in Revance Therapeutics, Inc. in Q4 2017 and held it in 4 quarters.
Parallax Volatility Advisers's Revance Therapeutics, Inc. position peaked at $1.24M in Q4 2017.
186 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2023.

Based on Parallax Volatility Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.